Amgen logo — #WeareBiotech

Amgen

#WeareBiotech

Founded 1980 United States Thousand Oaks, United States 40947 employees IPO Total: $32.51B Biotechnology, Health Care +2

General Information

Company Name Amgen
Founded Year 1980
Location United States Thousand Oaks, United States +9
Founders / Decision Makers
Team member
Employees 40947
Industries Biotechnology, Health Care, Manufacturing +1
Funding Stage IPO
Social

Get notified when Amgen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Amgen is exhibiting robust strategic growth in mid-2026, marked by the successful launch of a new DLL3-targeting therapy for extensive-stage small cell lung cancer and its immediate market entry into the European Union. This product-driven expansion is underpinned by significant recent Post IPO Debt financing, including a $4 billion raise in February 2026, indicating continued investment in its innovative pipeline and global reach. Concurrently, the company maintains strong public trust, earning recognition as one of America's Most Trustworthy Companies.

Signal Types
Product Launch Expansion Funding Recognition Event Participation
Strategic Labels
Oncology Expansion International Market Entry Pipeline Commercialization
Next Move: Market Expansion
·
Impact: 9/10
·
Ideal For: Large-Cap Biotech Investors — Public Equity

About Amgen

Amgen, founded in 1980, has been a cornerstone of the biotechnology and pharmaceutical industries. Known for its slogan #WeareBiotech, the company leverages biology and technology to combat severe diseases, striving to enhance and extend human lives. Amgen's commitment to research and development has facilitated a robust pipeline that supplements its existing portfolio targeting cancer, heart disease, osteoporosis, and both inflammatory and rare diseases.

As a distinguished member of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen's innovative prowess was recognized in 2024 as one of the "World’s Most Innovative Companies" by Fast Company and one of "America’s Best Large Employers" by Forbes. Headquartered in the United States, Amgen's last notable financial activity includes a substantial $4.00 billion post-IPO debt investment, strengthening its strategic positioning within the market. Amgen continues to be a substantial player in the health care sector, with a reputation supported by its extensive history and recent financial growth.

Taxonomy: Human Genetics, Innovative Medicines, Cancer Treatment, Cardiovascular Health, Osteoporosis Treatment, Inflammatory Diseases, Rare Diseases, Oncology, Hematology, Nephrology, Neuroscience, Biologics, Research and Development, Human Therapeutics

Services & Products

Therapeutics Development
Clinical Research
Healthcare Solutions
Scientific Innovation

Target Customers

Healthcare Professionals Patients with Serious Illnesses Biotech and Pharma Industry

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Debt •••••• - 01 Feb 2026
Post Ipo Equity •••••• 1 •••• •••• 01 Jan 2024
Post Ipo Equity •••••• 1 •••• •••• 01 Mar 2023
Post Ipo Debt •••••• 2
Investor Investor
01 Dec 2022
IPO •••••• - 01 Jun 1983

View All 6 Funding Rounds

Amgen Alternatives & Competitors

View All Alternatives
Amgen vs

Dragging Tomorrow Into Today.

IPO
1154 employees
Amgen vs
CSL Plasma
CSL Plasma United States

Plasma Donation

5911 employees
Health Care
Amgen vs

We’re here to champion long-term health. Get updates on innovation and inspiring stories 💙

IPO
62491 employees
Biotechnology, Pharmaceutical

FAQ About Amgen

#WeareBiotech
Amgen was founded in 1980.
Amgen is headquartered in Thousand Oaks, United States.
Amgen operates in the following industries: Biotechnology, Health Care, Manufacturing, Pharmaceutical.
Amgen has approximately 40947 employees.
Amgen has completed 6 funding rounds, raising a total of $32.51B. The latest funding stage is IPO.
Amgen offers: Therapeutics Development, Clinical Research, Healthcare Solutions, Scientific Innovation.
Top alternatives and competitors to Amgen include Sarepta Therapeutics, CSL Plasma, Novo Nordisk, Daiichi Sankyo US, Vertex Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Amgen and Sarepta Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Amgen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy